Vir Biotechnology
VIR
8.39
-0.48
-5.41%
Vir Biotechnology
US · VIR
#2824 by market cap
Listed 2019
8.39
-0.48
-5.41%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $17Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15Market Newswire · 2026/8/8
-
Company notice
Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.SEC · 2026/5/29
-
Company notice
Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.SEC · 2025/6/3
-
Rating change
Vir Biotechnology Is Maintained at Buy by HC Wainwright & Co.Dow Jones · 2026/10/7
-
Company notice
Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.SEC · 2025/2/26
-
Rating change
Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/9/29
-
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $22Market Newswire · 2026/11/10
-
Rating change
Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17Market Newswire · 2026/9/30
-
Here's What Analysts Are Forecasting For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Third-Quarter ResultsSimply Wall St · 2026/11/7
-
Rating change
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22Benzinga · 2026/10/7
-
Company notice
Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.SEC · 2024/6/4
-
Rating change
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $22Market Newswire · 2026/10/7
-
Rating change
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $11.77 to $30Market Newswire · 2026/11/6
-
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $22 to $30Market Newswire · 2026/11/11
-
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/12
-
Company notice
Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.SEC · 2024/4/3
-
Rating change
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/9/22
-
U.S. Stock Market Watch: Vir Biotechnology Plunges Over 14% in Pre-Market Trading as Share Offering Dilutes Float by ~11% and Prices at a DiscountGelonghui Finance · 2026/11/13
-
Rating change
Vir Biotechnology Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.Dow Jones · 2026/10/7
-
Rating change
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30Market Newswire · 2026/8/6
-
Rating change
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30Market Newswire · 2026/8/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)TipRanks · 2026/6/11
-
Rating change
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27Market Newswire · 2026/6/11
-
Rating change
Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy RatingMarket Newswire · 2026/5/27
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vir Biotechnology discussion 0 comments